grenoble-isère-france · €200-billion medical technology market, on the ... global x-ray imaging...

G r e n o b l e - I s è r e - F r a n c e

• Technological breakthroughs in:medical and surgical robotics, bioinformatics, healthcare information systems,imaging, diagnostics,drug delivery systems.

• Global medtech leaders and innovative start-ups.

• An innovation ecosystem unparalleled in Europe.

• A testing ground for new developments in « e-healthcare » and the « silver economy »

Local MedTech industry in excellent shape

AEPI 2014

AEPI - MedTech 20142

The number of new drugs released on the market each year has been on the decline for the past decade. The €200-billion medical technology market, on the other hand, has been growing steadily for fifty years and is now bustling along at a growth rate of 10% per year. Industry heavyweights such as GE Healthcare, Becton Dickinson, Roche Diagnostics, and Covidien—four of the global medtech industry “big ten”—have set up operations in Grenoble-Isère. The local area is also home to many smaller, yet no less innovative, companies including Tornier, the number-one in shoulder and hip prostheses; global X-ray imaging leader Trixell; and bioMérieux, which develops groundbreaking solutions for in vitro diagnostics.

Medical technology is today a major driver of medical advances. However, this highly-fragmented industry is characterized by seemingly-disparate products and services covering fields such as imaging, diagnostics, biochips, surgical robotics and software, sensors, instrumentation, prosthetics, implants, e-healthcare, and assisted living.

Companies that design and manufacture products for preventive, diagnostic, and therapeutic medicine and patient monitoring—along with their suppliers and the developers of the technologies that go into their products—are all part of the medtech ecosystem. This multidisciplinary industry, at the crossroads of healthcare and technology, leverages a broad array of expertise to develop applications for some of the latest advances in fields like physics chemistry, materials, IT, biotech, and micro- and nanotechnology.

Digital technologies are offering deeper insights into living organisms, opening up a world of new possibilities in diagnostics, treatments, and patient outcomes. These technologies also underpin personalized healthcare, which aims to better-target preventive and therapeutic medicine to individual patient needs. Digital technologies also enable developments such as communicating medical systems, which will see rising demand as the population ages.

Introduction

Grenoble-Isère, an international hub for micro- and nanotechnology and software, is the ideal location for companies seeking to carve out a position in the rapidly-growing medtech industry.

The area is home to some of the world’s best research centers. The local innovation ecosystem has attracted leading multinationals and has spurred the creation of a growing cohort of start-ups. Local organizations, including Medic@lps, Tasda, and the Minalogic and Lyonbiopôle clusters are also active participants in the medtech industry, providing a range of services to support innovation, from training through R&D project engineering and help securing financing.

AEPI - MedTech 2014 3

Introduction Contents

From biotech to e-healthcare ....................................................................................................................... 4

Grenoble University Hospital Center — Leading the way in innovation and clinical trials ...................................................................................................................................................... 6

Computer-assisted medicine and surgery — Grenoble-Isère, where pioneering innovations are born ............................................................................................... 8

Drug delivery systems — Getting treatments to their target .............................................10

Bioinformatics and healthcare information systems — Software to power medtech solutions ....................................................................................................................................................12

Medical imaging — Fuelling the expansion of personalized medicine ........................ 14

Medical diagnostics — Home to global leaders and innovative start-ups ................16

The silver economy — Local stakeholders leading the way .................................................18

Medical research and innovation — A unique ecosystem .................................................... 20

Higher education — Multidisciplinary programs designed to meet medtech needs ......................................................................................................................................................... 25

Development opportunities for all medtech stakeholders .................................................. 27

Grenoble-Isère medtech industrial actors ........................................................................................ 28


Biotechnology & pharmaceuticalsBiotherapies (recombinant-protein, stem-cell, and neural and functional cell-culture therapies) and personalized medicine.Drug development, FDA-approved manufacturers, vaccines, and aromatic molecules.

Implants, microsystems & prosthesesMiniaturized implantable and non-implantable medical systems (implantable cardiac defibrillators and pacemakers).Biocompatible materials and prostheses.MEMS and nanomaterials.

Drug-delivery systems (DDS)Injection and IV, anesthesia, and micro-injection systems.Packaging. Nanoparticles and targeted drug delivery.

Medical equipment & instrumentationSurgical robotics and augmented medicine and surgery.Medical imaging (radiological detectors, X-ray, gamma-ray, synchrotron radiation, tomography, and fluorescence imaging).Medical equipment for assisted living (modelling of physical space and movement, embedded and non-embedded sensors).Laboratory and research instrumentation, cell culture materials, crystallography.

DiagnosticsIn vivo (molecular imaging, preclinical imaging, reagents, radioactive tracers, fluorescent markers, biopsy systems). In vitro (nanomaterials, nanostructures, biomarkers, microfluidics, and biochips such as DNA chips and labs-on-chip).

Engineering & servicesIT (medical and healthcare management software, patient data management software, databases, bioinformatics, modelling).Contract Research Organizations (clinical trials, regulatory consulting). Consumables.Assisted living services.

From biotech to e-healthcare


From biotech to e-healthcare

Drug-delivery systems (D

DS)

Implants, microsystems &

pro

stheses

Biotec

hnolo

gy & pharmaceuticals

Engin

eering & services

Diagnostics

Medical equipment &

instr

umen

tatio

nInnovative Pharmaceutical Packaging

...

...

...

...

...


Grenoble University Hospital Center

The Grenoble University Hospital Center (CHUG) is one of the region’s leading healthcare facilities. It is also one of Grenoble-Isère’s largest employers, with an 8,000-strong staff from more than 100 professions, each of which contributes to the center’s missions of teaching, research, and patient care. The center is divided into six specialized units (imaging, biology, pharmacy, research, public health, and OR) and conducts world-caliber biomedical research in robotics for neurology and minimally-invasive surgery. It also boasts recognized expertise in research, and clinical, biological, and—above all—technological development.

The center’s well-structured research programs are built on a large number of partnerships and address clearly-defined, high-potential research areas which include neuroscience, chronic disease, life sciences engineering, cancer, ontogenesis, infectious agents, and procreation.

France’s 3rd leading center for neurosurgery & trauma centerRanked 13th in France by budget and range of care offered1,045 clinical trials in progress led by:

35% Medical/pharmaceutical companies26% Academic research labs24% Grenoble University Hospital Center17% Other teaching hospitals

130,000 inpatient stays/year650,000 outpatient consultations per year91,000 ER admissions/year€620 million annual operating budget8,000 employees (including 1,800 healthcare professionals)

Targeted organizations to support research within CHUG

Clinical trials are crucial to getting new drugs and other treatments to patients. They are also a necessary step in the process of developing new medical technologies. And to make the process smother, more effective, and faster, the center’s research unit works closely with partners such as Grenoble University, the French National Center for Scientific Research (CNRS), the French Institute of Health and Medical Research (Inserm), the French Alternative Energies and Atomic Energy Commission (CEA), the French Blood Bank (EFS), the European Synchrotron Radiation Facility (ESRF), and the Institute for Structural Biology (IBS), among others, via several organizations:

In Ovo, ultra-sensitive in vitro testing

In Ovo develops and sells the world’s only ultra-sensitive early tests capable of simultaneously measuring potential drugs’ efficacy and toxicity before animal or human trials are performed. The tests use the embryonic eggs of chickens, amniotes similar to mammals, to provide a faster, more complete, more reliable, and less costly method of testing than current models can offer.

• A Center for Clinical Investigation to support biologists, clinicians, and researchers; which features a unit especially dedicated to technological innovation (CIC-IT),

• A Biology Resource Center (CRB) for cancer research.• The Clinatec research center, which develops and tests innovative

approaches leveraging micro- and nanotechnology and electronics, primarily in the field of neurostimulation.


Speeding the innovation process

The Center for Clinical Investigation-Technological Innovation (CIC-IT), located on the Grenoble University Hospital Center campus, is one of the eight technological innovation facilities in France to have earned certification from Inserm, the French National Institute for Healthcare and Medical Research. The lab’s aim is to help bring innovations to maturity as quickly as possible, with research activities ranging from clinical proof-of-concept studies to therapeutic value assessments.

CIC-IT’s Maxithec, a lab that aims to boost the effects of expert targeted therapies, is France’s only research organization to focus on medical systems for augmented surgery. The lab also develops new tools and methods to assess the therapeutic value of innovative medical systems—a significant competitive advantage for the manufacturers of those systems.

Grenoble University Hospital Center’s CIC-IT boasts more than two decades of experience in healthcare information systems engineering. It is a place where clinicians, researchers, and manufacturers can work together at every step of the way (design, prototyping, pre-series manufacturing, and therapeutic value assessment) to get medtech innovations to patients faster.

A major provider of clinical research services

The CRO (contract research organization) Biomatech is Europe’s leading provider of consulting and preclinical and clinical trials for medical systems and the associated biotechnologies. Biomatech holds all of the necessary accreditations and has pharmaceutical-company status under French law. With more than 100 employees (including 30 research scientists) and 25 years of experience, the company, a subsidiary of US based NAMSA (acquired in 2004) brings proven expertise in areas such as clinical studies and testing, safety testing, and therapeutic value assessments of medical systems. The company also provides microbiological testing services and training for manufacturers and surgeons.

NAMSA is the world’s leading CRO, providing a broad range of services to medical equipment manufacturers for over 45 years. The company delivers particular expertise in product safety testing, clinical research, and regulatory compliance.

Leading the way in innovationand clinical trials

In Ovo, ultra-sensitive in vitro testing

In Ovo develops and sells the world’s only ultra-sensitive early tests capable of simultaneously measuring potential drugs’ efficacy and toxicity before animal or human trials are performed. The tests use the embryonic eggs of chickens, amniotes similar to mammals, to provide a faster, more complete, more reliable, and less costly method of testing than current models can offer.


Computer-assisted medicine and surgery

Today’s hospitals are equipped with advanced technical facilities that use robotics and digital imaging to deliver improved patient care. Most notably, today’s “high-tech” medical systems help surgeons perform more precise, less invasive, and safer procedures for better patient comfort and clinical outcomes. Computer-assisted medicine and surgery covers technologies such as medical and surgical robotics, surgical navigation, and simulation.

For more than 25 years, the Grenoble area has stood out for groundbreaking R&D partnerships involving clinicians, research scientists, and manufacturers. Their exemplary teamwork has resulted in the emergence of innovative medical systems that give surgeons immediate information about their patients during a procedure and guide them during complicated procedures, among them biopsies and prosthesis implantation, making those procedures safer. Tens of thousands of patients have already benefitted from medtech advances developed by researchers at Grenoble labs such as TIMC-IMAG, a joint lab of Joseph Fourier University and CNRS (see below), as well as Grenoble University Hospital Center clinicians, and medical systems manufacturers.

ECCAMI, the Excellence Center for Computer Assisted Medical Intervention, was founded in 2010 to bring together clinicians, research scientists, and manufacturers from across the Rhône-Alpes region. CAMI, which received funding under France’s national LabEx program, unites six joint academic research labs from across France for partnerships with clinicians and manufacturers. The goal is to develop innovations that are medically effective, economically viable, and widely adoptable.

TIMC-IMAG blends clinical and technological research advances

The applications-focused TIMC-IMAG lab studies medical imaging techniques from an IT and mathematics angle. It is a joint research unit of Joseph Fourier University (UJF) and the French National Center for Scientific Research (CNRS). Scientific researchers and clinicians work together on ways to use IT and applied mathematics to better understand and control normal and pathological processes for biology and healthcare. The lab’s multidisciplinary research helps further scientists’ basic knowledge of these topics and fuels the development of new systems for both diagnostic and therapeutic medicine.

The lab’s computer-assisted medicine and surgery team, set up in 1985, has pioneered advances in medical and surgical robotics and instrumentation, for example. Most of the team’s research is conducted in partnership with the Grenoble University Hospital Center and, especially, the center’s CIC-IT unit (see page 7).

TIMC-IMAG is also very active in technology transfer and has spun off eighteen start-ups, including Endocontrol and Koelis.


Computer-assisted medicine and surgery

A visionary center dedicated to innovation enhancement

ECCAMI (the Excellence Center for Computer Assisted Medical Interventions) supports the emergence of new technologies and their transfer to medical-systems manufacturers. The center, founded in 2010 by Joseph Fourier University and Grenoble University Hospital Center, brings together clinicians, scientific researchers, and manufacturers. The center’s 30 members include Inria, CEA-Leti, CNRS, Grenoble Institute of Technology, Thales, and around 20 innovative start-ups. The center’s activities cover all aspects of medicine—surgery, interventional radiology, radiotherapy, clinical assistance, and more— that could benefit from computer assistance, with techniques ranging from surgical robotics and navigation to minimally-invasive surgery and healthcare information systems. ECCAMI’s areas of expertise include 3D bone and organ models and databases, software for computer-assisted medicine and surgery, sensors, interventional imaging, mesh matching, in vivo tissue elasticity measurement, 3D modelling, navigation, planning and simulation, medical robotics, image processing, and data fusion.

The center’s resources were developed to support all stages of the technology development and transfer process:

Guiding the surgeon’s handEndoControl, founded in 2006, makes robotics systems for endoscopic surgery. The company has leveraged strong research partnerships to develop compact, innovative instruments that improve the ergonomics of minimally-invasive surgery. Vicky, the company’s first robot, is voice controlled. It lets surgeons position an endoscope during surgery without assistance. The company’s second product, Jaimy, released in early 2014, replicates the movements of surgical instruments inside the patient during minimally-invasive surgical procedures.

Grenoble-Isère, wherepioneering innovations are born

•Research labs within TIMC-IMAG•Labs for testing on mannequins and anatomical specimens; access to hospital

departments •A dedicated room in the Joseph Fourier University anatomy lab for

experimentation with anatomical specimens and validation of the design, ergonomics, and fitness-for-use of medical devices developed by partner manufacturers

•A technology showroom for computer-assisted surgery presentations and demos.


Drug-delivery systems (DDS)

For the past two decades the advent of new therapeutic molecules and advances in nanomedicine have fuelled the development of new drugs capable of targeting very precise areas of the human body. To keep the active substances in these drugs from losing their effectiveness before they reach the area to be treated, more precise drug delivery systems are needed. Developing these systems requires know-how from a wide range of disciplines, from mechanics and electronics to chemistry and materials. And, increasingly, these drug delivery systems draw on the latest innovations in digital, micro-, and nanotechnologies.

Grenoble-Isère is a hub for cutting-edge developments in drug delivery systems; the region is home to market leaders, among them Becton Dickinson, Fresenius Kabi, and Nemera (formerly Rexam Healthcare), which develops and manufactures its insulin pens locally. In addition to these major players, Grenoble-Isère also boasts a slate of dynamic small businesses such as Eveon, which has successfully harnessed local know-how in micromechanics, mechatronics, electronics, and MEMS (microelectromechanical systems). Eveon worked with CEA-Leti for three years to develop the first silicon “smart drug delivery” micropump using standard MEMS fabrication processes. The system’s high volume and extreme precision will cut injection times and improve patient comfort, and, because less of the drug is wasted, it will also save money. Eveon’s drug delivery system is a prime example of how healthcare professionals, major research centers, and academic labs can combine their complementary know-how to get new innovations to patients faster.

Becton Dickinson: An active contributor to Grenoble’s economy for over 50 years

Becton Dickinson (BD) is one of the world’s leading medtech companies. It designs, manufactures, and markets medical systems, testing instruments, and medical reagents. BD first set up operations in France in 1958. Nearly 1,600 people work at the company’s site in Pont de Claix. All of BD’s global business segments (BD Medical, BD Diagnostics, and BD Biosciences), business units, and corporate functions are represented at the Pont de Claix site.

A large part of the company’s injectables business is run out of the Pont de Claix site, which is also home to a prefillable glass syringe production unit (for the BD Medical segment’s Pharmaceutical Systems division). The Pont de Claix site has earned recognition for innovation and high-added-value manufacturing. The company invests nearly €20 million per year (2011–2015) to keep the site’s manufacturing equipment at the industry’s state of the art.


IV equipment design and manufacturing specialist

Fresenius Kabi brings more than 30 years of experience in designing and manufacturing IV equipment. The company’s comprehensive lineup of syringe pumps, IV pumps, and IV stations covers the full spectrum of hospital needs, from general to specialized care units in addition to ICUs and operating rooms. The company leverages know-how in electronics, IT (embedded and systems), and mechanics to develop products for IV anesthesia, intensive care, and other hospital applications, as well as homecare. Fresenius Kabi’s Brézins site in Isère counts 400 employees, serves as the company’s global competency center for IV and nutrition equipment, and is home to three divisions:

• R&D and manufacturing•Commercialization •Strategic marketing

Breaking new ground in smart drug injection systems

Eveon, based in Montbonnot near Grenoble, designs, develops, and assembles completely-automated drug preparation and delivery systems (by nebulization, spray, or injection). The company custom-develops and manufactures its products—from the reconstitution of lyophilized drugs to the injection of viscous drugs—in association with pharmaceutical and biotech companies. Eveon’s systems are based on three major innovations:

Eveon recently formed a partnership with Alaxia, a biotechnology company that develops new treatments for the most serious respiratory diseases, to create a home-based production system for use in treating cystic fibrosis.

The new partnership, which follows Eveon’s 2012 acquisition of Alpao, a maker of deformable mirror and adaptive optics, brings Eveon additional know-how in imaging for diagnostics and firmly positions the company in the vision sciences.

Getting treatments to their target

•Suitability for all types of primary containers (vials, cartridges) •A micropump to control drug preparation (lyophilized drugs, liquid-liquid

blends, etc.) and inject drugs with precision volumes from the μl to the ml scale

• Integrated skin, fluid, air, and pressure sensors that control all drug preparation and injection parameters


Bioinformatics and healthcare information systems

The growing complexity of medicine is in step with the increasing performance of information technology. For applications spanning diagnostics, imaging, genomics, complex biological systems, and personalized medicine, today’s information systems must cope with massive amounts of data—requiring unique and innovative approaches to statistics and data processing. Solutions must be found to standardize and store data so that they can be analyzed, tracked, and shared—with the ultimate goal of helping caregivers more accurately diagnose and treat patients.

And the issues are many. How do you model medical knowledge? Or complex molecules? How do you share medical data quickly, effectively, and securely? How do you save and reuse data? Processing medical imaging data, presenting patient data in a useable form, and modeling biological interactions are just some of the many challenges this highly interdisciplinary field is tackling.

Healthcare information systems must do more than just process large amount of data; to add value to medicine, they must also provide new analytical models and compare them with the results of medical experiments. And Grenoble-Isère is home to a host of professionals poised to provide relevant solutions.

Local software makers such as Technidata (software for biology resource centers and labs), EquiTime (healthcare staff schedule management software), and Alma (which developed a software suite for hospitals in partnership with Grenoble University Hospital Center), are helping pioneer advances.

Excellence in digital research

Inria Grenoble-Rhône-Alpes (France’s National Institute for Research in Computer Science and Automation), founded in 1992, boasts 34 research teams and employs 610 people. The institute is a leading R&D center for simulation, image interpretation, modelling, data processing and representation, distributed and high-performance computing, and modelling complex phenomena. Inria has spun off 23 start-ups since 1998 and is involved in R&D projects coordinated by four clusters, including Minalogic and Lyonbiopôle. A half-dozen research teams at the institute are working on multidisciplinary projects combining IT and healthcare and that cover a broad range of topics from evolutionary biology to drug efficacy.


Biological data analysis software and services

Genostar provides a comprehensive range of bioinformatics and database solutions for microbial (viruses, bacteria, and yeasts) genome, transcriptome, protein, and metabolic analysis. The company also offers bioanalysis services encompassing genome sequencing, annotation, and comparison, as well as raw data assembly. Genostar’s software and databases are available via an integrated platform for a seamless microbial genome analysis and comparison workflow.

IT solutions for testing labs

Software developer Technidata is based in Montbonnot, just outside of Grenoble. The company develops IT solutions for biological resource centers and labs, offering a full range of lab and biobank management software, as well as a comprehensive lineup of services from consulting and project management to custom software development, training, and technical support. The company’s products are sold in more than 25 countries, where they are used in fields such as biochemistry, hematology, immunology, serology, virology, microbiology, molecular biology, genetics, anatomo-cytopathology, and biobank management.

A global expert backed by local center of excellence

Persistent Systems, founded in 1990, is a global leader in software and IT services, in particular for life sciences and healthcare applications. The company’s Life Sciences Division targets the analytical chemistry instrumentation, LIMS, bioinformatics, medical device, clinical trial database, e-healthcare, and care management markets. In 2011 the company acquired Agilent Technologies’ center of excellence, which today employs around 40 people.

The specialist in shared patient medical files

Calystene, founded in 1992, develops medical and administrative IT solutions for streamlined business processes, increased compliance with procedures, broader information sharing, and more secure care processes. The company has built up more than 20 years of experience and is today recognized as an expert in shared patient medical files, nominative drug prescription and dispensation, healthcare procedures, and secure drug circuits, as well as in the technical management of rehabilitation, imaging, and specialist practitioner units in conjunction with hospitals.

Software to power medtech solutions


Medical imaging

Demand for medical imaging services is on the rise. Recent technological advances have made medical imaging a powerful tool for exploring the human body—and the key to widespread deployment of personalized medicine. Medical imaging, when combined with a patient’s biological data, can make the difference in terms of early diagnosis and more individualized, better targeted treatment.

Molecular imaging lets us actually see cells and molecular processes at work. And the technology is driving advances in patient care—particularly in oncology, where it is helping doctors diagnose tumors earlier and more precisely, administer more targeted treatments, and assess the efficacy of a drug instantaneously. And, thanks to companion tests and biomarkers, molecular imaging can even be used to predict and validate the efficacy of a drug’s active ingredient, making it a useful tool along the entire medtech value chain, from basic research and new drug development to patient care.

Medical imaging professionals are currently restructuring their resources to adapt to the challenges that will be posed by new medical treatments stemming from today’s biotech research. An ever-broadening field of investigation spanning molecular and cellular biology has paved the way for developments such as tracers specific to certain diseases, for example, those used in Fluoptics’ optical imaging system for cancer surgery, which has just obtained FDA approval for the US market.

Grenoble-Isère is home to a number of companies that have risen to global leadership positions in certain segments of the medical imaging market. Trixell, based in Moirans, near Grenoble, is the world’s leading manufacturer of digital detectors for medical radiology; e2v designs and manufactures a line of sensors for digital radiographic imaging—used in dental diagnostics—at its plant in Saint-Egrève, also near Grenoble.

The FLI-Grenoble network of excellence in biomedical imaging

FLI (France Life Imaging) is a national research network focusing on biomedical imaging. The network aims to push back the frontiers of today’s in vitro imaging technologies, develop a unified line of superior-quality services, and raise France’s profile in this dynamic industry.

The national network is made up of six regional branches, one of which is in Grenoble. FLI-Grenoble was created from a partnership between Joseph Fourier University, the French National Center for Scientific Research (CNRS), Inserm, Grenoble University Hospital Center, CEA-Leti, and ESRF. It brings together chemists, physicists, engineers, technology experts, biologists, pharmacists, and MDs specializing in preclinical and clinical research in in vivo imaging.

The network boasts a broad range of equipment covering all types of imaging (MRI, pre-operative MRI, nuclear imaging, optical imaging, intravital microscopy, MEG/EEG for neurophysiology, and monochromatic X-ray) and offering levels of performance that exceed what is currently available on the market.


Innovative fluorescence imaging for surgery

Fluoptics has developed an in vivo optical imaging system (Fluobeam®) and a fluorescent tracer (Angiostamp™) with tumor-targeting capacities. When used together, the two products let surgeons see actual biological processes and cancer cells that would be invisible to the naked eye in real time during a surgical procedure. That means doctors can identify a tumor’s edges with a great degree of precision, reducing the risk of damaging healthy tissue or leaving cancerous cells behind. The result is fewer relapses. The company was founded in 2009 to develop and market instrumentation technology invented in CEA-Leti’s labs. The technologies that underpin Fluoptics’ tracer were developed at Joseph Fourier University in conjunction with the CNRS and Inserm.

The global leader in digital detectors for medical imaging

Trixell, founded in 1997, is a joint venture between Thales Electron Devices, Philips Healthcare, and Siemens Healthcare (all three of which are global leaders in diagnostic and surgical systems). Trixell designs and manufactures flat-screen digital detectors, using a technology that leverages the company’s own sensors to convert X-rays to digital signals. The system can be used in a broad range of medical radiology applications. In addition to helping reduce the X-ray dosages to which patients are exposed, the technology helps improve diagnostics. Most notably, the technology facilitates the transmission and storage of X-ray images and is compatible with a broad range of image-processing techniques. Trixell is located in Moirans, near Grenoble.

Fuelling the expansion of personalizedmedicine

One of the world’s leading manufacturers of medical imaging equipment

The American GE Healthcare (European HQ in UK), is one of the world’s leading manufacturers of medical imaging equipment. The company stands out for its extensive range of products and services, which, in addition to medical imaging equipment, also include new drug development and biopharmaceutical product manufacturing. GE Healthcare’s mission is to speed the development of tomorrow’s medical technologies and revolutionize healthcare by helping researchers identify and better understand disease—and doctors better diagnose and treat patients.

Thomson CGR, located in Isère since 1975, became GE Healthcare in 1990. The company’s technologies and services for healthcare professionals are intended to improve the use of medical imaging equipment, medical diagnostics, and patient management systems.


Medical diagnostics

The medical diagnostics market is undergoing unprecedented change due to by the advent of personalized medicine and the emergence of new testing-lab business models. This transformation is further accentuated by the relentless quest for efficiency in healthcare systems and individualized treatments that draw on increasingly large amounts of data. In this landscape, manufacturers must ensure that their medical diagnostic systems meet healthcare professionals’ needs for increasingly precise results. Sample sizes are shrinking (often around a microliter), biochips are becoming increasingly common, readers are now pocket-sized, and labs are integrating advances in microfluidics and nanotechnologies—many of which were invented in Grenoble.

Grenoble-Isère is home to some of the world’s leading names in medical diagnostics (Roche Diagnostics and bioMérieux), major research centers (CEA), and vibrant start-ups (Avalun, ImmunID, and others). In addition, internationally-recognized synergies between publicly-funded research and private-sector R&D have made Grenoble—and France’s entire Rhône-Alpes region—one of the country’s major centers for the development and clinical testing of innovative in vitro diagnostic systems. The Christophe Mérieux Center, born from over a decade of collaboration between bioMérieux and the CEA, is a prime example.

Immune-system profiling for personalized medicine

ImmunID, spun off of a CEA-Grenoble lab in 2005, specializes in molecular diagnostics of the immune system for the pharmaceutical and medical diagnostics markets. The company develops products and services for testing the immune repertory at genome level. ImmunID’s tests measure a patient’s immune defenses and provide additional insight to help caregivers deliver personalized treatments. The company’s technology was first used to monitor patients during cancer treatment.

A pocket-sized lab

Avalun, a recent spin-off of CEA-Leti, is developing a portable in vitro diagnostic system that can perform multiple biological tests simultaneously. The system is designed for healthcare professionals and patients seeking to play a more active role in their own care. At its core is the LabPad® reader—poised to ride the growing trend toward e-healthcare—and a range of consumables that professionals and patients can use to perform various tests from a single drop of blood.


Developing tomorrow’s diagnostics’ solutions in Grenoble

A leader in in vitro diagnostics and infectious diseases, bioMérieux was founded in 1963 and now operates in more than 150 countries. Today, the company is renowned for its know-how in clinical diagnostics and industrial microbiological quality control testing. The company’s strategy is driven by technological and scientific innovation and is backed by heavy investment in R&D programs run by the company’s own multidisciplinary staff, with the support of numerous international partnerships and alliances. For example, bioMérieux has been working with CEA-Leti since 1997 through a joint multidisciplinary team to develop innovative in vitro diagnostic systems. In 2006, the company located its Christophe Mérieux Center for Molecular Biology in Grenoble, near the CEA and MINATEC campuses.

bioMérieux has two sites in Grenoble-Isère:

The global leader in histopathological diagnostics

Roche is the world’s leader in in vitro diagnostics and histological cancer diagnostics, and is paving the way to major innovations in diabetes management. Roche Diagnostics France, a Roche subsidiary entirely dedicated to diagnostics, is France’s number-one biological diagnostics company. Headquartered in Meylan, near Grenoble, since 1977, Roche Diagnostics France employs 650 people and markets a comprehensive lineup of products and services for research, biological testing, histopathology, and diabetes. Roche Diagnostics France acquired US-based Ventana Medical Systems in 2008, propelling the company to its current position as a global leader in histopathological diagnostics. The company’s Meylan site is home to its diabetes, medical biology, and research business lines, as well as its international customer support and training centers.

Home to global leadersand innovative start-ups

•The Christophe Mérieux Center in Grenoble, which employs nearly 200 people and is home to the company’s molecular biology activities. It houses a state-of-the-art research unit comprising chemistry, biology, molecular biology, and systems engineering labs. The site also has a production unit dedicated to manufacturing and improving reagents.

•The company’s center for expertise in microbiology, which employs more than 400 people, including more than 200 research scientists in microbiology, engineering, and IT. The center is located in La Balme les Grottes.


The silver economy

The world’s population is aging: by 2035, senior citizens will make up a third of the people on the planet. This huge demographic shift is at the root of major societal and economic transformations, and developed countries are on the front lines. They must now rapidly adapt their public healthcare systems to survive in this new environment. However, the “silver economy” will also present new opportunities. The demand for assisted living solutions will mushroom, creating a high-potential new market. Research firm HIS forecasts that the global in-home healthcare market will double over the next six years, soaring from €5.7 billion in 2013 to €12.8 billion in 2018.

And with that opportunity comes challenges such as how to improve treatments, shorten hospital stays, mitigate the risks associated with elderly patients living alone, and ensure that medical care is available in rural and other underserved areas. More comprehensive in-home care, better coordinated medical and social services, improved safety, and solutions for independent living are just some of the goals that scientists are striving to reach. And digital and “geron-” technologies will play a pivotal role by driving advances in remote patient monitoring and diagnostics—both of which will help improve the quality of care and reduce the number of hospital stays.

Improving the healthcare continuum is now a healthcare policy priority in many countries. To rise to this challenge, both human and technical resources will need to be deployed, both in patients’ homes and remotely. In Isère, local governments are backing a variety of e-healthcare programs, one of which is the Autonom@Dom® independent living program spearheaded by the Isère General Council.

Grenoble-Isère is known as a hub for science and technology. However, it is also an ideal proving ground for experimental initiatives to develop the technology and processes needed to meet the growing demand for in-home healthcare and assisted living solutions. Local nonprofit organizations TASDA and Medic@lps, the regional I-Care cluster, and global competitive clusters Minalogic and Lyonbiopôle play a crucial role liaising with and rallying local experts around these emerging issues.

Autonom@Dom®, a living lab for an enhanced patient care continuum

The Autonom@Dom® program consists of an integrated healthcare and social services portal offering a range of services available 24 hours a day, seven days a week, in addition to personalized human assistance and technical solutions—all designed to enable in-home care. The program aims to break down the silos that currently separate healthcare and social services for an enhanced patient care continuum, particularly for the elderly in need of assisted living solutions and people with chronic disease. Some 800 people will receive services over the two years of the program. The goals are to assess changing business processes in healthcare and social services, evaluate integrated technical solutions and the associated business models, and eventually deploy the program locally, nationally, and perhaps even internationally.


Smart biodetector makes independent living safer

Vigilio, founded in 2005, develops systems capable of distinguishing normal everyday situations from critical situations requiring emergency assistance. The company’s Vigi’Fall™ fall detection unit consists of a biosensor equipped with radio communication capabilities, a body patch worn by the user, sensors, and a control center.

Coordinating partnerships to conceive tomorrow’s assisted living services

TASDA, a nonprofit organization focusing on in-home healthcare and assisted living, was founded by the Grenoble University Hospital Center, Minalogic, and local governments. It is an “expert” member of France’s national center for in-home healthcare and assisted living. TASDA’s role is to liaise between in-home healthcare and assisted living stakeholders, from solutions providers, healthcare and social services professionals, and academics to subsidized housing providers, government agencies, financers, prescribers, and users. In practical terms, TASDA provides businesses and local governments with insights into tomorrow’s healthcare needs, the technological solutions in the pipeline, and knowledge of the stakeholders and markets involved.

Digital technologies for the elderly

Technosens, founded in 2007, develops and markets a simplified multimedia communication system called e-lio. This interactive system is designed to keep the elderly in touch with family members and healthcare providers through a video sensor and a user-friendly combined telephone handset/remote control unit. The system provides an easy-to-use videoconferencing experience right on the user’s TV screen. Users can receive messages, photos, and videos and access a range of services including meal delivery, home automation, entertainment, fall prevention, and more—right from their homes.

Complete remote patient monitoring services

H2AD® operates and manages a complete range of around-the-clock remote healthcare and patient monitoring services. The company located to Grenoble in July 2013 to be near the city’s research centers, and today offers continuous remote patient monitoring systems that combine human resources (a call center) and technical capabilities (communicating scales, remote activity monitoring, and more) to follow-up on inpatient care once patients are released from the hospital and to monitor patients suffering from serious chronic diseases.

Local stakeholders leading the way


Medical research andinnovation

Grenoble-Isère boasts a thriving scientific community poised to respond to the major challenges facing the life sciences and healthcare sectors. Whether for basic or clinical research, local businesses have access to major international scientific research instruments and a broad range of laboratories. And, in Grenoble-Isère, opportunities to work with leading scientists through R&D partnerships abound. Manufacturers have partnered with Grenoble University research labs, the Grenoble University Hospital Center (via CIC-IT Maxithec), local branches of the French National Center for Scientific Research (CNRS), the CEA, Inserm, and Inria, to name a few. The region is home to some 200 research teams working on computer-assisted medicine and surgery, micro- and nanotechnology for medicine (local researchers file more than 40 patents in this burgeoning field each year), in vitro diagnostics and medical imaging, new materials, tissue engineering, bioinformatics, healthcare information systems, and e-healthcare.

The local research ecosystem is anchored by R&D centers at the leading edge of medicine and some of the world’s largest scientific instruments for observing matter. EMBL (the European Molecular Biology Laboratory), IBS (Institut de Biologie Structurale), Institut Albert Bonniot (for research on molecular oncogenesis and ontogenesis), GIN (Grenoble Neuroscience Institute), Institut Jean Roget (for genomics research), ILL (Institut Laue Langevin), and ESRF (the European Synchrotron Radiation Facility)—along with active academic research—fuel Grenoble-Isère’s capacity to conduct innovative, multidisciplinary work in the field of healthcare. ESRF, a member of the Structural Biology Group, possesses a dedicated beamline for medical research to characterize matter and materials of all types, including biological tissues and molecules.

Of course, the presence of leading international labs is just the beginning. The region’s attractiveness also hinges on its multiple R&D partnerships and medtech industry organizations and facilities that foster networking and pool research and development resources (such as open-access labs, clusters, and professional associations). All of these advantages help drive business competitiveness and move the medtech industry forward.

Medic@lps, Founded in 2002, the Grenoble-Isère healthcare cluster counts 70 members including start-ups, SMBs, corporations, research centers, universities, and local governments, all united in their commitment to developing medical technologies, biotechnologies, and e-healthcare technologies. Medic@lps is uniquely positioned to serve businesses, with a management board made up mostly of entrepreneurs. The cluster’s programs—group services and individual assistance—are designed to support its members’ growth in a given industry. And, with a vast network spanning the globe (including a shared office in Boston), Medic@lps is poised to help its members penetrate international markets.



The global competitive cluster Minalogic, founded in Grenoble in 2005, counts 236 members specializing in micro and nanotechnology and digital solutions. Minalogic has set up a healthcare workgroup with around 40 active members. The group’s aim is to give businesses and research labs an opportunity to share knowledge in four main research and development areas: :

The cluster has certified and helped secure financing for around ten R&D projects in remote healthcare, medical imaging, assisted surgery, miniaturized pacemakers, and the development of microsystems to deliver drugs’ active ingredients.

Lyonbiopôle, another of the region’s global competitive clusters, focuses on infectious diseases in humans and animals from a holistic perspective, from diagnostics and prevention to treatment and treatment administration systems. The projects certified by the cluster aim to develop innovative diagnostic, preventive, and therapeutic medical advances and the associated administration systems, with the overall goal of making medicine more responsive and personalized. The target markets are: infectious diseases, cancer, autoimmune diseases, rare diseases, inflammatory diseases, and more. Lyonbiopôle has 139 members and has certified 145 R&D projects since 2005, for total R&D spending of €710 million, €285 million of which was government-funded.

The I-Care cluster brings together stakeholders from across the medtech value chain and throughout the Rhône-Alpes region. The cluster’s mission is to support businesses in their implementation of innovative strategies to respond to changing markets and improve their business environment, making them more competitive. Members include businesses, universities, research centers, healthcare facilities, and nonprofits.

A unique ecosystem

• Instrumentation for research, diagnostics, and personalized medicine • In-home healthcare and assisted living, shared patient medical files•Augmented medicine and computer-assisted medicine and surgery•Technical assistance and substitution systems, implanted systems


Clinatec is a cross-disciplinary applied medical research center, spearheaded by internationally-renowned neurosurgeon Dr. Alim-Louis Benabid, 2014 Lasker-DeBakey Clinical Medical Research Award. Located on the MINATEC innovation campus, Clinatec aims to develop and test innovative medical treatment strategies leveraging the latest advances in micro- and nanotechnology and electronics. The center, an initiative of CEA-Leti in partnership with Grenoble University Hospital Center, Joseph Fourier University, and Inserm, is unlike any other medical research center in the world. It aims to respond to major biomedical needs in the treatment of cancer, neurodegenerative diseases, and spinal-cord injuries. Clinatec houses a range of joint R&D projects involving academic research labs and manufacturers, in order to forge the necessary synergies among clinicians, engineers, and biologists.

Around €40 million was invested to build the 6,000 m² Clinatec facility, which boasts preclinical research labs, biology labs, and a pilot hospital unit with six patient rooms, a post-surgical recovery room, and an operating room equipped with the latest technology such as a neurosurgery robot and intraoperative MRI.

One of Clinatec’s flagship projects is a brain-controlled exoskeleton to help quadriplegic patients regain the use of their limbs. The system is directly implanted in the patient’s cranium, on the surface of the motor cortex, eliminating the need to implant electrodes in the patient’s brain. Its 64 sensors capture the motor cortex signals generated by the patient’s intent to move. Ultimately, the implantable system will be used to operate a new generation of exoskeleton developed by CEA-List researchers at a lab in Grenoble. The exoskeleton R&D project also involves developing software to decode brain signals and transform them into movements.



The NanoBio innovation center was launched in 2001 by CEA-Grenoble, Joseph Fourier University, and Grenoble University Hospital Center. It houses scientific equipment for research in micro- and nanotechnology for biology and healthcare applications. Professionals from research (more than 300 scientists in chemistry, physics, materials, biology, medicine, and electronics), higher education, and industry work together interactively via the center to pursue two objectives:

NanoBio focuses mainly on active wearable and implantable medical systems, with:

NanoBio leverages all of the advantages of the MINATEC innovation campus, including expertise in micro- and nanotechnology and infrastructure featuring the High-Tech Building (BHT), which houses high-tech companies on the campus. NanoBio also draws on the nearby Clinatec applied medical research center and Grenoble University Hospital Center, where preclinical and clinical trials are performed.

Biopolis is a business incubator and resource center coordinated by Joseph Fourier University. It provides office and lab space and support services to innovative young companies entering the healthcare market. The incubator boasts 2,000 m² of facilities, including 27 offices available for lease and 12 lab rooms. It is conveniently located in a medical park next to Grenoble University Hospital Center, the Institut Albert Bonniot (IAB), and IN3S (the Institute for Healthcare IT and Engineering).

The ground floor is dedicated to dry biology research (medtech, robotics, and software) and has a microscopy room and microsystems labs. The wet biology lab, upstairs, offers molecular biology and biochemistry labs, a P2 lab, two cell culture labs, a fully-equipped washing and sterilization room, and machine room.

Businesses, whether in the early start-up phase or already established, can access a full range of technical and administrative support services and enjoy close proximity to research centers (Grenoble University Hospital Center, ECCAMI, Joseph Fourier University, and others) and other companies. They also benefit from an environment that facilitates experimentation and navigation through the different phases of the start-up process, from the validation of new technology to prototyping.


A unique ecosystem

• Design and develop new miniaturized systems to improve testing, diagnosis, and treatment of numerous diseases

• Promote the dissemination of new knowledge in the life sciences and healthcare and transfer that knowledge to industry

•Labs-on-chip •Active wearable medical systems•Cell architecture research•A proteomics resource center•Biochips and functional genomics.


Higher education

Grenoble-Isère is home to more than 61,000 students, making it one of France’s biggest University towns. With a wide variety of top-quality degree programs (particularly in the sciences, in which 42% of the city’s students are enrolled), Grenoble’s universities benefit from a strong international reputation—reflected in the 7,200 international students from 180 different countries who study here. Local life sciences and healthcare-related degree programs enroll some 9,000 students (mostly at Joseph Fourier University).

Degree programs in the life sciences and healthcare-related disciplines are continuously updated to meet the rapidly-changing needs of research organizations and businesses operating in this fast-paced sector. Over the past two decades, Grenoble University has pioneered advances in France’s medical-school landscape, developing integrated university-hospital programs, clinical internships, and cross-disciplinary curricula.

Grenoble’s institutions of higher learning have developed numerous programs to meet the unique needs of the medtech industry. These multidisciplinary programs stand apart in that they address both the scientific and industrial aspects of medical technologies.

Doctoral schools

•Chemistry & Life Sciences (EDCSV) The Doctoral School for Chemistry & Life Sciences is known for its sharp focus on activities at the crossroads of disciplines such as biology, chemistry, medicine, pharmacy, and physics, with a particular emphasis on highly-interdisciplinary experimental approaches. The school boasts a number of different labs in and around Grenoble that conduct high-profile research in cellular and molecular biology, structural biology, molecular chemistry, and physical chemistry

•Engineering for Healthcare, Cognition, and the Environment (EDISCE)The Doctoral School for Healthcare, Cognition, and the Environment specializes in data acquisition, processing, and modelling to better understand the mechanisms at work in living systems, examining their relationship to their environment, cognition (perception and decision), and action (control and effectuation).

One of Europe’s biggest college towns

61,300 students7,200 international students4 universities7 engineering schools29 engineering majors265 Master’s degree programs14 doctoral schools


Joseph Fourier University, offering programs in the sciences, technology, and healthcare

The Joseph Fourier University regularly appears in all of the major international rankings. It boasts a student body of more than 17,000, as well as fourteen academic departments in Grenoble and an extension campus in Valence. As part of its mission to prepare students for the major healthcare challenges of tomorrow, the university offers both general and highly-specialized degree programs.

• Medicine and pharmacy The university’s programs in medicine and pharmacy (5,000 students) stand out for their innovative teaching and exceptionally enriching scientific environment.

• Healthcare information systems engineeringThe university’s program in healthcare information systems engineering was first launched ten years ago at Polytech Grenoble (the Joseph Fourier University’s engineering department) in association with Grenoble University Hospital Center and research lab TIMC-IMAG. The program prepares tomorrow’s engineers to interface between healthcare, IT, and instrumentation, with courses in signal and image processing and clinical measurement, for example.

• Engineering for healthcare and drug developmentThis Master’s program offers eight specializations spanning medtech, pharmacy, biotech, and the relationships between healthcare and the environment. It prepares budding scientists, engineers, doctors, project managers, and clinical research associates to develop and test technological innovations leveraging healthcare information systems, modeling, and medical imaging.

• International program in biohealth computingThis Erasmus Mundus program, offered at the Master’s and Ph.D. levels, prepares tomorrow’s healthcare-industry executives to support multidisciplinary research programs combining biotechnology, clinical research, environmental health, and mathematical modeling.

Grenoble Ecole de Management (GEM) Master’s in Biotechnology Management

This program was developed in 2002 to meet the growing demand in the life sciences industry for multidisciplinary competencies in biomedical science and management. Students who complete the program come away with a strong

scientific background (Ph.D.; Pharm.D.; MSc in biology or chemistry, for example) as well as solid business skills suitable for positions such as product manager,

marketing manager, IP consultant, technology transfer manager, and business developer.

Multidisciplinary programs designed to meet medtech industry needs


MEDTECH INDUSTRY CHALLENGES

The medtech industry is currently facing a number of challenges, from discovering new, more effective, and better targeted molecules to developing complete therapeutic systems encompassing diagnostics, data analysis, treatment selection, drug delivery, and services for patient monitoring and assisted living.

NEw OppORTUNITIES FOR DIGITAL TECHNOLOGIES

In addition to offering a level of technological know-how unrivalled in Europe, Grenoble-Isère is also one of the only places in the world where a truly multidisciplinary approach to scientific research is used to develop miniaturized medical systems, innovative diagnostic tools, surgical robots, and groundbreaking imaging equipment. The area is also located near Lyon, a pharmaceutical-industry hub, and a thriving plastics industry in and around Oyonnax.

players from the micro- and nanotechnology and digital industries—both labs and manufacturers—are driving the emergence of innovative new medical applications for existing technologies and, in some cases, new medtech products. The advanced technologies being developed in Grenoble-Isère in fields such as electronics, microsensors, software, and robotics, to name a few, are boosting the added value of medtech solutions.

Digital technologies are fuelling the growth of in-home healthcare and assisted living services—and Grenoble-Isère is leading the way. For instance, Ivès is a company that develops and implements remote healthcare services for the hearing impaired and the dependent individual. And Orange Labs in Meylan, near Grenoble, coordinates Orange’s innovation-related activities in the field of e-healthcare.

Electronics and embedded intelligence are playing an increasingly central role in medical systems. Grenoble-Isère has attracted a number of companies seeking the know-how and talent needed to carve out a position on this market. STMicroelectronics, a major figure in the local innovation ecosystem, is placing its bets on medical applications for its low-energy signal processing, MEMS, sensor, and actuator technologies.

The company also supplies high-security microprocessors for tomorrow’s personalized healthcare cards. Movea, a spin-off of CEA-Leti, is the global leader in motion sensing technology for medical applications. Memscap provides Carmat with pressure sensors and accelerometers for the company’s autonomous artificial heart. And Maatel, an electronics engineering and scientific instrumentation firm, designs and manufactures medical electronics (for IV automation, diagnostics, and electrosurgical equipment).

Sensor miniaturization and innovations in micro-energy sources like batteries and micro-fuel-cells are now opening up new possibilities for the design of extremely compact diagnostic and measurement devices. PaxiTech, which manufactures small fuel cells, is working on a portable external energy source designed specifically for the healthcare market. And the TIMC-IMAG lab is developing another major innovation in the form of an implantable biobattery that is charged by the glucose produced by the human body.

A NEw SOURCE OF GROwTH FOR “TRADITIONAL” MANUFACTURING INDUSTRIES

Innovation is not reserved for so-called high-tech companies. Businesses in industries such as plastics, for instance, are leveraging their know-how and innovation capacity to conquer new markets. One example is ARaymondLife, founded in 2007 by industrial fastener manufacturer ARaymond as part of the company’s efforts to diversify. This venture into the healthcare market has spurred the company to develop innovative solutions for pharmaceuticals and medical diagnostics—namely, components for drug delivery systems and medical packaging systems. Another example is Stiplastics, which produces plastic packaging systems and pillboxes.

Development opportunitiesfor all medtech stakeholders


Company Website

Bio

tech

nolo

gy

Dia

gno

stic

s

Dru

g d

eliv

ery

syst

ems

Med

ical

equi

pm

ent

and

in

stru

men

tatio

n

Engin

eeri

ng a

nd

serv

ices

pharm

ace

utic

als

Med

ical i

mp

lant

s and

pro

sthe

tics

In V

itro

In V

ivo

Med

ical

equ

ipm

ent

Med

ical

imag

ing

Instr

umen

tatio

n

Surg

ical

robo

tics

Faci

litie

s

Bioi

nfor

mat

ics

Con

sum

able

s

CRO

Who

lesa

lers

and

reta

ilers

Softw

are

A3 Surgical www.a3surgical.com •Aatlantide www.aatlantide.com •Abiolab www.abiolab.fr •Acom Sante •Advanced Liquid Logic France www.liquid-logic.com •Advicenne Pharma www.advicenne.com •Aenova www.aenova.de •Ahlstrom www.ahlstrom.com •Alchimedics •Alliadis (Cofdsi) www.alliadis.com •Alma www.alma.fr •Alpao www.alpao.fr •Alpes Instruments www.alpes-instruments.com •Alumed www.alumed.fr •ARaymondlife www.araymondlife.fr •Ardes www.ardes-france.com •Aryballe Technologies •Avalun www.avalun.com •Basan France International VWR Gp www.basan.com •BD www.bd.com •Beckman Coulter Genomics www.beckmangenomics.com •Bellin Creation www.bellin-creation.com •Bgene Genetics www.bgene-genetics.com •Bio-Logic www.bio-logic.info •BioMérieux www.biomerieux.fr •Biotem www.biotem.fr •Bizmedtech www.bizmedtech.com •Blue Ortho www.blue-ortho.com •Boiron Laboratoires www.boiron.com •Cad4bio www.cad4bio.com •Calystene www.calystene.com •CEIES (Centre d'Etudes de l'Impact de l'Environnment sur la Santé) www.ceies.fr •Cellipse www.cellipse.com •CERP Rhin Rhône www.cerp-rrm.com •Cezame Connexions www.cezame-connexions.fr •Chabloz Orthopedie www.chabloz-orthopedie.com •Climatic Entreprise www.climatic-entreprise.com •Cogitop www.cogitop.fr •Covidien Manufacturing Grenoble (Medtronic) www.covidien.com •Creacell www.creacell.com •

Grenoble-Isère medtech industrial actors


Cytoo www.cytoo.com •Delta Consultants www.delta-consultants.com •Deltalab www.deltalab.fr •Demeure Orthopédie www.demeureorthopedie.com •Deva Laboratoires www.deva-lesemotions.com •Ecrins Therapeutics www.ecrins-therapeutics.com •Endocontrol www.endocontrol-medical.com •EquiTime www.equitime.fr •Er2i Ingenierie www.er2i.eu •Eras Labo www.eras-labo.com •Eticeo Sante www.eticeo.com •Eurofins Optimed www.optimed.fr •Eveon www.eveon.eu •Faure QEI www.faure-qei.com •FDI France Medical www.fdifrance.com •FEI - VSG www.vsg3d.com •Finorga - Novasep Gp www.novasep.com •Fisher Bioblock Scientific fr.fishersci.com/fr/ •Fluoptics www.fluoptics.com •Fresenius Kabi www.fresenius-kabi.fr • •Gambro Industries www.gambro.fr •General Electric Medical Systems www.gehealthcare.com •Genostar www.genostar.com •GHW - Mediplus www.ghwgroup.fr •Gmg www.gmg-injectionplastique.com •Habitat et Santé www.habitatetsante.net •Helioscopie www.helioscopie.fr •Hemosquid •Herboristerie Chartreuse www.herboristerie-chartreuse.com •Imactis www.imactis.com •IMeBio www.imebio.com •ImmunID www.immunid.com •Inlab Healthcare www.inlabth.com •Inovo www.tests-inovo.com •Interactivite Video Système-Ives www.ives.fr •Irlynx www.irlynx.com •Isis www.isis-robotics.com •Jarmat - ADP Laboratoire www.adplaboratoire.com •Kalys www.kalys.com •Keystone Dental www.keystonedental.com •Koelis www.koelis.com •

Company Website

Bio

tech

nolo

gy

Dia

gno

stic

s

Dru

g d

eliv

ery

syst

ems

Med

ical

equi

pm

ent

and

in

stru

men

tatio

n

Engin

eeri

ng a

nd

serv

ices

pharm

ace

utic

als

Med

ical i

mp

lant

s and

pro

sthe

tics

In V

itro

In V

ivo

Med

ical

equ

ipm

ent

Med

ical

imag

ing

Instr

umen

tatio

n

Surg

ical

robo

tics

Faci

litie

s

Bioi

nfor

mat

ics

Con

sum

able

s

CRO

Who

lesa

lers

and

reta

ilers

Softw

are


Kowok Theragnostic www.kowok-theragnostic.com •LXRepair www.lxrepair.com •Maatel www.maatel.com •Maincare Solutions (ancien Mckesson) www.maincare.fr •Manudo Médical - GP Fimodo www.manudo.fr •Mape RGA www.mape-rga.fr •MBA Consulting www.mbaconsulting.fr •Medartis www.medartis.com •Mellitech www.mellitech.com •Meunier-Carus Médical www.meunier-carus.com •Micropoint Bioscience www.micropointbio.com •Microvitae Technologies www.microvitae.com •Minitubes www.minitubes.com •Minmaxmedical •Movea www.movea.com •Namsa www.namsa.com •Nano-H www.nano-h.com •Naturamole www.naturamole.com •NatX-ray www.natx-ray.com •Nemera (ancien Rexam Healthcare) www.nemera.net •Nexus/Optim fr.nexus-ag.de •Novacyl www.novacyl.eu •Novitom www.novitom.com •OCP Répartition www.ocp.fr •Odontec www.odontec.fr •OMNIlife Science (ancien Praxim) www.omnils.com •Orkyn’ www.orkyn.fr •Orthotaxy www.orthotaxy.com •Patheon France www.patheon.com •PDC Line Pharma www.pdc-line-pharma.com •Pharm’Depo www.pharmdepo.fr •PharmUp www.pharmup.fr •Promise Advanced Proteomics www.promise-proteomics.com •PX'Therapeutics www.px-therapeutics.com •Quarness www.quarness.fr •Raumedic AG www.raumedic.com •RBI www.rbi-instrumentation.com •RBP Pharma www.rbppharma.com •Rhône-Alpes Labo www.rhonealpeslabo.fr •Roche Diagnostics France www.roche-diagnostics.fr •RTD www.rtdental.fr •

Company Website

Bio

tech

nolo

gy

Dia

gno

stic

s

Dru

g d

eliv

ery

syst

ems

Med

ical

equi

pm

ent

and

in

stru

men

tatio

n

Engin

eeri

ng a

nd

serv

ices

pharm

ace

utic

als

Med

ical i

mp

lant

s and

pro

sthe

tics

In V

itro

In V

ivo

Med

ical

equ

ipm

ent

Med

ical

imag

ing

Instr

umen

tatio

n

Surg

ical

robo

tics

Faci

litie

s

Bioi

nfor

mat

ics

Con

sum

able

s

CRO

Who

lesa

lers

and

reta

ilers

Softw

are


Saphymo www.saphymo.fr •Sensaris Cyberfab www.sensaris.com •Shimitek www.shimitek.com •Sleepinnov Technology www.sleepinnov.com •Small Infinity •Smartox Biotechnology www.smartox-biotech.com •Sober Laboratoire www.sober.fr •Sobioda www.sobioda.eu •Soframedical www.soframedical.com •Softin Systèmes www.softin.fr •Sorin CRM www.sorin.com •Stabyl www.stabyl.fr •Stanley Healthcare Solutions France www.stanleyhealthcare.com •Stemcell Technologies www.stemcell.com •Stiplastics www.stiplastics.com •SurgiQual Institute www.surgiqual-institute.com •Surgivisio www.surgivisio.com •SynapCell www.synapcell.fr •Synthelis www.synthelis.fr •Technidata www.technidata-web.com •Technosens www.technosens.fr •The Binding Site Limited www.bindingsite.com •Thierry Baboulin www.baboulin.com •Thomassin Laboratoires www.audition-thomassin.fr •Tornier www.tornier.com •Toxibionte www.toxibionte.fr •Trixell www.trixell.com •Ugin Dentaire www.ugin-dentaire.fr •Univéo www.univeo.fr •UroMems www.uromems.com •Valtronic www.valtronictechnologies.com •Vigilio www.vigilio.fr •X Medical Picture www.xmedicalpicture.com •Xenocs www.xenocs.com •

Company Website

Bio

tech

nolo

gy

Dia

gno

stic

s

Dru

g d

eliv

ery

syst

ems

Med

ical

equi

pm

ent

and

in

stru

men

tatio

n

Engin

eeri

ng a

nd

serv

ices

pharm

ace

utic

als

Med

ical i

mp

lant

s and

pro

sthe

tics

In V

itro

In V

ivo

Med

ical

equ

ipm

ent

Med

ical

imag

ing

Instr

umen

tatio

n

Surg

ical

robo

tics

Faci

litie

s

Bioi

nfor

mat

ics

Con

sum

able

s

CRO

Who

lesa

lers

and

reta

ilers

Softw

are

Â The world’s 5th most inventive city

(Forbes, July 2013)

Â The highest concentration of research jobs

in France

Â A local ecosystem with a global reach: 4 out of 10

local manufacturing jobs are with foreign-owned

firms, and the US, Germany, and the UK are

leading the way in local business investment

AEPI-November2014.Photocredits:PierreJayet-Inria–H.Raguet–P.Stropa–StudioPons–P.Avavian–A.Aubert–BioMérieux–CHU–Eccami–Fotolia–Shutterstock–Evéon–BD-In-ria-JFBachas-Inria-G.Cottet--Trixell–D.Michon–Roche–Fotolia–StudiodeWinter–Technosens–Tasda–IAB–H.Martin–M.Buscail

The agency strives to promote the benefits of doing business in Grenoble-Isère nationally and internationally with the goal of attracting new businesses to the area.

Your bridge between Grenoble-Isère and the world.

The agency focuses its efforts on the rest of Europe and the United States, and also runs a number of programs targeting Asia with the support of the Invest in France Agency.

Over the past fifteen years, the agency has helped 440 businesses—both French- and foreign-owned—move to Grenoble-Isère, contributing to the creation of 9,800 jobs.

The agency’s added value lies in its capacity to create the necessary conditions for effectively identifying and attracting manufacturing businesses that could benefit from a foothold in Grenoble-Isère, and then giving them the support they need to move here—and stay here for the long term. The area’s cross-cutting ecosystem encompassing higher education, research, and industry provides particularly fertile ground for starting a new business or growing an existing one. The agency leverages local economic development expertise with a vast, deep network of relevant contacts to give both businesses and local governments the keys to successful development.

The Grenoble-Isère Economic Development Agency (AEpI)

1, place Firmin Gautier – 38027 Grenoble Cedex 1 – France

Tél : 04 76 70 97 18 – Fax : 04 76 70 97 19 – Email : [email protected]

Grenoble-Isère, France:A bright future in smart systems

The Grenoble-Isère Economic Development Agency (AEpI)The Grenoble-Isère Economic Development Agency is tasked with promoting investment and economic development.

grenoble-isère-france · €200-billion medical technology market, on the ... global x-ray imaging...

Documents